Abilita Therapeutics, Inc. and Finnish Orion Corporation have entered into a collaboration to leverage Abilita's pioneering EMP™ antibody discovery platform for challenging multi-span membrane protein (MMP) targets, with a focus on oncology and pain. Orion has an option to license an undisclosed Abilita discovery program and select two additional MMP targets for drug discovery over the collaboration period. Abilita has the potential to earn up to $785 million plus royalties on commercial sales